Olon Group
Rodano (Milan), Italy
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (9)
○ EMA GMP
○ MHRA GMP
Quick Facts: Olon Group
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Rodano (Milan), Italy
- Modalities
- Small Molecule API, HPAPI / Cytotoxics, Microbial Fermentation, Mammalian Cell Culture, Recombinant Proteins / Enzymes, Biologics (mAbs), ADC (end-to-end bioconjugation), Oligonucleotide / Peptide, Chemical Synthesis, Semi-Synthesis
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Olon Group
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSmall Molecule API, HPAPI / Cytotoxics, Microbial Fermentation, Mammalian Cell Culture, Recombinant Proteins / Enzymes, Biologics (mAbs), ADC (end-to-end bioconjugation), Oligonucleotide / Peptide, Chemical Synthesis, Semi-Synthesis
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (10 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press9 articles
Broad modality coverage (10 modalities)
Recent News 9 articles
Olon announces the appointment of Roberta Pachera as Vice President of CDMO Small Molecules and Global Key Account Division - Manufacturing Chemist
Olon Group Acquires GTP Bioways - Contract Pharma
Olon Group Announces Two Leadership Appointments - Contract Pharma
Antheia and Olon continue biomanufacturing partnership - Manufacturing Chemist
Olon Group acquires GTP Bioways to expand biotech offering - Manufacturing Chemist
OLON GROUP ANNOUNCES THE ACQUISITION OF GTP BIOWAYS GROUP - DCAT Value Chain Insights
Olon Group Strengthens Its Leadership in Bioproduction with Two Strategic Appointments in France - Koreabizwire
Olon acquires HuvePharma - Speciality Chemicals Magazine
Olon commits to ultra-potent compound manufacturing expansion with new €25m facility - Manufacturing Chemist
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Small Molecule API CDMOs →
HPAPI / Cytotoxics CDMOs →
Microbial Fermentation CDMOs →
Mammalian Cell Culture CDMOs →
Recombinant Proteins / Enzymes CDMOs →
Biologics (mAbs) CDMOs →
ADC (end-to-end bioconjugation) CDMOs →
Oligonucleotide / Peptide CDMOs →
Chemical Synthesis CDMOs →
Semi-Synthesis CDMOs →